Most recent study on patients who have experienced positive or even mystical effects brought on by the psychedelic ingredient known as the psychoactive component of “magic mushrooms,” psilocybin, has shown that these benefits may linger for up to a year.
According to the results of this research, some recreational drugs may be used to alleviate the stress associated with chronic conditions like cancer, provided that they are taken in a responsible way and the proper dose is employed.
Even though only one dose of the medication was administered to the 36 patients who took part in the first trial, the results of the follow-up research showed that they still believed the experience had positive impacts.
Many new studies on microdosing mushrooms are being planned or are currently underway in the United States, including those that are presently in progress. In the aim that a single dose of psilocybin will have a positive and long-lasting impact on cancer patients, several trials are being done.
New study published in the Journal of Psychopharmacology1 is the continuation of an experiment conducted by Griffiths and colleagues in 2006, in which they delivered large dosages of psilocybin to 36 volunteers who described themselves as “spiritually oriented” but had never used hallucinogens. Two months after participating in a meeting, several of the participants said that it had had a long-lasting and positive influence on their life because they were encouraged to go within themselves.
One year after taking part in psilocybin research trials, patients report still experiencing positive effects. R. Griffiths and his colleagues deserve a lot of credit for their work.
The microdosing mushrooms were given to seminary students in a church for the Good Friday Experiment in 1963, which had comparable results for theology students. Many 1960s experiments were only partly followed up on since they were not submitted to any type of peer review at the time. If the life-enhancing characteristics that people described in 2006 were still present, Griffiths was keen to use updated assessments from more recent studies.
Illusionary state of mind
There was just one person, out of the initial 22, who still met the Pahnke-Richards Mystical Experience Questionnaire criteria for a “full” mystical experience 14 months later.
Sixty-seven percent of participants said that treatment was one of their top five most spiritually significant experiences, and 17 percent said it was their most profound spiritual experience overall after 14 months. 60% of those who participated reported an increase in either their sense of well-being or contentment with life as a result of taking part in the study Microdose
It is a questionnaire that was completed in retrospect and on a sample of spiritually inclined individuals that the study is based on. In the scientific community, this raises a lot of questions, and it may be useful in medicine.
In a better mood
In contrast, UC Los Angeles School of Medicine Professor Charles Grob has finished treating his last patient in a study using psilocybin to relieve cancer worry. At the University of California, Los Angeles, researchers performed the investigation. Transcendental or transpersonal experiences during psychedelic therapy, he claims, were associated with significant reductions in anxiety, increased mood, and an overall higher quality of life for patients with terminal cancer during the 1950s and 1960s studies he cites.
Clinical conditions that are notoriously difficult to treat may now have a treatment option according to the study’s results. Although psychedelics are frequently seen as especially difficult to work with, they have the potential to make therapeutic breakthroughs in patients who have previously shown a high level of resistance and inability to respond. While this research is now safe, it must nevertheless be carried out with considerable care.